Abstract
Background
Rrisk of infection and hospitalization after transrectal prostate biopsy (TRBx) has been increasing worldwide. Several modified antibiotic regimens have met with variable success in preventing such infections. Transperineal prostate biopsy (TPBx) is increasingly recommended as the preferred alternative due to a potentially lower risk of post-biopsy infections. Aim of this review is to define the magnitude of post-biopsy complications and the effectiveness of preventive strategies, including TPBx approach.
Methods
We performed a focused review of literature on infectious complications after TRBx and detailed the use of various preventive measures. We summarized the effectiveness of several preventive measures, including TPBx, and outlined the inconsistencies in reported outcomes. We identified potential barriers to the uptake of TPBx, including the gap in knowledge such as lack of high-quality evidence.
Results
Several antibiotic prophylaxis protocols, including targeted and augmented, have been utilized for TRBx without demonstrating a clearly superior regimen. Of the non-antibiotic preventive measure, povidone-iodine rectal prep appears to be most effective strategy. Several single-arm cohort studies have reported very low rates of infections after TPBx and demonstrated the feasibility of an office-based procedure. However, barriers to the adoption of TPBx exist including retrospective data, and conflicting results showing minimal reduction in complications with increased burden of resource utilization. Presently, there are no randomized studies comparing the infectious complications after TRBx and TPBx. We discuss the rationale and protocol for a randomized controlled trial to determine the comparative effectiveness of biopsy techniques.
Conclusions
TPBx approach has the potential to lower the rate of post-biopsy infections and hospitalizations. However, there are several barriers to widespread adoption of this approach including inconsistencies in reported outcomes and lack of Level-1 evidence. Randomized controlled studies are required to directly compare the infectious complications associated with each biopsy procedure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC Jr. Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol. 2004;22:7–10.
Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013;189:2039–46.
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–77.
Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017;72:250–66.
Evans R, Loeb A, Kaye KS, Cher ML, Martin ET. Infection-related hospital admissions after prostate biopsy in United States men. Open Forum Infect Dis. 2017;4:ofw265.
Centers for Disease Control and Prevention. Infographic: antibiotic resistance the global threat. Centers for Disease Control and Prevention; 2019. https://www.cdc.gov/globalheal.
Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22:438–45.
Chung HS, Hwang EC, Yu HS, Jung SI, Lee SJ, Lim DH, et al. Prevalence of fluoroquinolone-resistant rectal flora in patients undergoing transrectal ultrasound-guided prostate needle biopsy: a prospective multicenter study. Int J Urol. 2018;25:278–83.
Roberts MJ, Macdonald A, Ranasinghe S, Bennett H, Teloken PE, Harris P, et al. Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution. Prostate Cancer Prostatic Dis. 2020. https://doi.org/10.1038/s41391-020-0263-x. [Epub ahead of print.]
Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353–65.
Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, et al. Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology. 2017;104:11–21.
Skouteris VM, Crawford ED, Mouraviev V, Arangua P, Metsinis MP, Skouteris M, et al. Transrectal ultrasound-guided versus transperineal mapping prostate biopsy: complication comparison. Rev Urol. 2018;20:19–25.
Wu YP, Li XD, Ke ZB, Chen SH, Chen PZ, Wei Y, et al. Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy. Infect Drug Resist. 2018;11:1491–7.
Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, et al. An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198:329–34.
Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol. 2014;192:1673–8.
Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189:S12–S8.
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830–4.
Gross MD, Alshak MN, Shoag JE, Laviana AA, Gorin MA, Sedrakyan A, et al. Healthcare costs of post-prostate biopsy sepsis. Urology. 2019;133:11–5.
Brown RW, Warner JJ, Turner BI, Harris LF, Alford RH. Bacteremia and bacteriuria after transrectal prostatic biopsy. Urology. 1981;18:145–8.
Pradere B, Veeratterapillay R, Dimitropoulos K, Yuan Y, Omar MI, MacLennan S, et al. Non-antibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol. 2020. https://doi.org/10.1097/JU.0000000000001399.
Pilatz A, Veeratterapillay R, Köves B, Cai T, Bartoletti R, Wagenlehner F, et al. Update on strategies to reduce infectious complications after prostate biopsy. Eur Urol Focus. 2019;5:20–8.
Sabbagh R, McCormack M, Péloquin F, Faucher R, Perreault JP, Perrotte P, et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol. 2004;11:2216–9.
Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol. 2012;187:1275–9.
Cussans A, Somani BK, Basarab A, Dudderidge TJ. The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int. 2016;117:725–31.
Cheung C, Patel HD, Landis P, Carter HB, Han M. Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: effect on hospitalization. Urol Oncol. 2018;36:158.e7–e12.
Liss MA, Kim W, Moskowitz D, Szabo RJ. Comparative effectiveness of targeted vs empirical antibiotic prophylaxis to prevent sepsis from transrectal prostate biopsy: a retrospective analysis. J Urol. 2015;194:397–402.
Jiang P, Liss MA, Szabo RJ. Targeted antimicrobial prophylaxis does not always prevent sepsis after transrectal prostate biopsy. J Urol. 2018;200:361–8.
Hadjipavlou M, Eragat M, Kenny C, Pantelidou M, Mulhem W, Wood C, et al. Effect of augmented antimicrobial prophylaxis and rectal swab culture-guided targeted prophylaxis on the risk of sepsis following transrectal prostate biopsy. Eur Urol Focus. 2020;6:95–101.
CDC. Antibiotic resistance threats in the United States, 2013. CDC; 2013. https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
Hu X-Y, Logue M, Robinson N. Antimicrobial resistance is a global problem—a UK perspective. Eur J Integr Med. 2020;36:101136.
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015;40:277–83.
Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007;52:1309–22.
Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010;13:71–7.
Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol. 2004;172:94–7.
Tu X, Liu Z, Chang T, Qiu S, Xu H, Bao Y, et al. Transperineal magnetic resonance imaging-targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer: systematic review and meta-analysis. Clin Genitourin Cancer. 2019;17:e860–70.
Winoker JS, Wajswol E, Falagario U, Maritini A, Moshier E, Voutsinas N, et al. Transperineal versus transrectal targeted biopsy with use of electromagnetically-tracked MR/US fusion guidance platform for the detection of clinically significant prostate cancer. Urology. 2020;146:278–86.
Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:31.
Loy LM, Lim GH, Leow JJ, Lee CH, Tan TW, Tan CH. A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection—comparing transrectal with transperineal approaches. Urologic Oncol: Semin Original Investig. 2020;38:650–60.
Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166:86–91.
Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, et al. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol. 2017;35:1199–203.
Vyas L, Acher P, Kinsella J, Challacombe B, Chang RT, Sturch P, et al. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases. BJU Int. 2014;114:32–7.
Johansen TEB, Zahl PH, Baco E, Bartoletti R, Bonkat G, Bruyere F, et al. Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. World J Urol. 2020;38:17–26.
Grummet J, Gorin MA, Popert R, O’Brien T, Lamb AD, Hadaschik B, et al. “TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis. 2020;23:62–5.
Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol. 2008;179:952–5.
Chang DT, Challacombe B, Lawrentschuk N. Transperineal biopsy of the prostate-is this the future? Nat Rev Urol. 2013;10:690–702.
Young R, Norris B, Reeves F, Peters JS. A retrospective comparison of transrectal and transperineal prostate biopsies: experience of a single surgeon. J Endourol. 2019;33:498–502.
Bennett HY, Roberts MJ, Doi SA, Gardiner RA. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect. 2016;144:1784–91.
Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget. 2017;8:23322–36.
Miah S, Eldred-Evans D, Simmons LAM, Shah TT, Kanthabalan A, Arya M, et al. Patient reported outcome measures for transperineal template prostate mapping biopsies in the PICTURE Study. J Urol. 2018;200:1235–40.
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.
Berry B, Parry MG, Sujenthiran A, Nossiter J, Cowling TE, Aggarwal A, et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int. 2020;126:97–103.
Tamhankar AS, El-Taji O, Vasdev N, Foley C, Popert R, Adshead J. The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of Hospital Episode Statistics data 2008–2019. BJU Int. 2020;126:133–41.
Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, et al. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018;21:524–32.
Holm HH, Gammelgaard J. Ultrasonically guided precise needle placement in the prostate and the seminal vesicles. J Urol. 1981;125:385–7.
Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71–4.
Bass EJ, Donaldson IA, Freeman A, Jameson C, Punwani S, Moore C, et al. Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer Prostatic Dis. 2017;20:311–7.
Stefanova V, Buckley R, Flax S, Spevack L, Hajek D, Tunis A, et al. Transperineal prostate biopsies using local anesthesia: experience with 1,287 patients. Prostate cancer detection rate, complications and patient tolerability. J Urol. 2019;201:1121–6.
Thurtle D, Starling L, Leonard K, Stone T, Gnanapragasam VJ. Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: a pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method. J Clin Urol. 2018;11:192–9.
Wetterauer C, Shahin O, Federer-Gsponer JR, Keller N, Wyler S, Seifert HH, et al. Feasibility of freehand MRI/US cognitive fusion transperineal biopsy of the prostate in local anaesthesia as in-office procedure-experience with 400 patients. Prostate Cancer Prostatic Dis. 2020;23:429–34.
Gorin MA, Meyer AR, Zimmerman M, Harb R, Joice GA, Schwen ZR, et al. Transperineal prostate biopsy with cognitive magnetic resonance imaging/biplanar ultrasound fusion: description of technique and early results. World J Urol. 2020;38:1943–9.
Kum F, Elhage O, Maliyil J, Wong K, Faure Walker N, Kulkarni M, et al. Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting. BJU Int. 2020;125:244–52.
Marra G, Zhuang J, Beltrami M, Calleris G, Zhao X, Marquis A, et al. Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases. BJU Int. 2021;127:122–30.
National Institute of Health. https://reporter.nih.gov/project-details/9973695.
Mian B. Prostate biopsy: efficacy and complications (ProBE-PC). 2020. https://clinicaltrials.gov/ct2/show/NCT04081636.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.
CONSORT 2010 Statement. Updated guidelines for reporting Parallel Group Randomized Trials. Ann Intern Med. 2010;152:726–32.
Acknowledgements
We would like to extend our appreciation to the research staff, Ms Brenda Romeo and Ms Laura Davey, for their support with the conduct of the study, and Dr. Sana Siddiqui for assistance with the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Mian, B.M., Kaufman, R.P. & Fisher, H.A.G. Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study). Prostate Cancer Prostatic Dis 24, 688–696 (2021). https://doi.org/10.1038/s41391-021-00352-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-021-00352-1
This article is cited by
-
Statistical analysis plan for the TRANSLATE (TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation of potentially clinically significant prostate cancer) multicentre randomised controlled trial
Trials (2024)
-
TRexit is going one step further
Prostate Cancer and Prostatic Diseases (2024)
-
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates
Prostate Cancer and Prostatic Diseases (2023)
-
Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores
World Journal of Urology (2022)
-
What level of evidence will it take to move towards widespread adoption of transperineal prostate biopsy in the USA?
Prostate Cancer and Prostatic Diseases (2021)